改良系统性红斑狼疮应答指数达标与长期临床结局的关联:一项五年前瞻性研究
本研究基于大型多中心纵向系统性红斑狼疮(SLE)队列,纳入2060例活动性疾病患者(基线SLEDAI-2K中位数8分),分析改良SLE应答指数(mSRI)达标与疾病活动度、糖皮质激素剂量、复发、损伤累积、狼疮低疾病活动状态(LLDAS)及缓解的关联。结果显示1年时56%患者达到mSRI应答,且应答者各年度疾病活动度和泼尼松龙剂量更低、LLDAS和缓解比例更高,第2、3年损伤累积更少;1年时mSRI应答状态可预测后续多数结局的临床获益。
要点
- 1年时56%的SLE患者达到mSRI应答,后续各年度应答率相似。
- mSRI应答者各年度疾病活动度和泼尼松龙剂量更低,LLDAS和缓解比例更高。
- 1年时mSRI应答状态预测后续损伤累积等多数结局的临床获益,损伤累积OR范围0.58-0.69(P < 0.05)。
核心结论
- 在活动性疾病并接受标准治疗的SLE患者中,mSRI达标可预测长期随访中的良好结局,支持将SRI达标作为SLE试验终点具有临床意义。
研究设计与样本
- 研究为前瞻性研究,使用大型多中心纵向SLE队列数据,患者接受标准治疗,随访至5年。
- 首次活动性疾病访视(SLEDAI-2K评分≥6)定为基线,从基线起每年评估mSRI达标情况直至5年。
- 共纳入2060例患者,基线SLEDAI-2K评分中位数为8。
主要发现
- 1年时56%的患者达到mSRI应答,后续各年度时间点应答率相似。
- 与无应答者相比,mSRI应答者各年度疾病活动度和泼尼松龙剂量显著更低,LLDAS和缓解达标比例更高,第2年和第3年损伤累积更少。
- 1年时mSRI应答状态可预测后续各年度多数结局的临床获益,包括损伤累积(OR范围0.58-0.69,各时间点损伤累积OR的P < 0.05)。
关键数值与推荐
- mSRI达标定义为SLEDAI-2K评分较基线降低≥4分且医师总体评估(PGA)恶化<0.3分。
- 活动性疾病定义为SLEDAI-2K评分≥6。
- 1年时mSRI应答率为56%。
- 1年时mSRI应答状态预测后续损伤累积的OR范围为0.58-0.69,各时间点损伤累积OR的P < 0.05。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In trials of systemic lupus erythematosus (SLE), the SLE Responder Index (SRI) is the most commonly used primary efficacy end point but has limited validation against long-term outcomes. We aimed to investigate associations of attainment of a modified version of the SRI (mSRI) with key clinical outcomes in SLE patients with up to 5 years of follow-up. METHODS: We used data from a large multicenter, longitudinal SLE cohort in which patients received standard of care. The first visit with active disease (defined as SLE Disease Activity Index 2000 [SLEDAI-2K] score ≥6) was designated as baseline, and mSRI attainment (defined as a reduction in SLEDAI-2K ≥4 points with no worsening in physician global assessment ≥0.3 points) was determined at annual intervals from baseline up to 5 years. Associations between mSRI attainment and outcomes including disease activity, glucocorticoid dose, flare, damage accrual, Lupus Low Disease Activity State (LLDAS), and remission were studied. RESULTS: We included 2,060 patients, with a median baseline SLEDAI-2K score of 8. An mSRI response was attained by 56% of patients at 1 year, with similar responder rates seen at subsequent annual time points. Compared to nonresponders, mSRI responders had significantly lower disease activity and prednisolone dose and higher proportions of LLDAS and remission attainment at each year, and less damage accrual at years 2 and 3. Furthermore, mSRI responder status at 1 year predicted clinical benefit at subsequent years across most outcomes, including damage accrual (odds ratio [OR] range 0.58-0.69, P < 0.05 for damage accrual ORs at all time points). CONCLUSION: In SLE patients with active disease receiving standard of care, mSRI attainment predicts favorable outcomes over long-term follow-up, supporting the clinical meaningfulness of SRI attainment as an SLE trial end point.
引用
- Connelly K, Kandane-Rathnayake R, Hoi A, et al. Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long-Term Clinical Outcomes: A Five-Year Prospective Study. Arthritis Rheumatol. 2022. PMID: 36122172. doi:10.1002/art.42350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。